Kovaltry Patient Assistance Program
Don’t let the high cost of brand recombinant factor VIII disrupt your hemophilia A treatment. We help eligible patients access Kovaltry (antihemophilic factor recombinant) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Kovaltry (antihemophilic factor recombinant, full-length) is FDA-approved for treatment and prophylaxis of bleeding in adults and children with hemophilia A. Standard-half-life full-length recombinant factor VIII — produced without human or animal plasma-derived additives. A trusted long-standing factor VIII option.
- Without assistance, Kovaltry costs commonly run approximately $12,000–$20,000+ per month for prophylaxis (weight and dosing-frequency dependent).
- Through AffordMyPrescriptions, qualifying patients can access Kovaltry for a flat $69.95 per month.
- Hemophilia A therapy landscape: standard-half-life recombinant factor VIII (Advate, Recombinate, Kogenate FS, Xyntha, Novoeight, Kovaltry); extended-half-life factor VIII (Adynovate, Eloctate, Nuwiq, Afstyla, Esperoct, Jivi, Altuviiio); non-factor therapies (Hemlibra — emicizumab bispecific antibody, weekly-to-monthly SC dosing); gene therapy (Roctavian — one-time IV for severe hemophilia A adults). Comprehensive Hemophilia Treatment Centers. National Hemophilia Foundation resources.
What is Kovaltry Prescription Assistance Program?
The Kovaltry Patient Assistance Program helps eligible patients access this recombinant factor VIII at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Kovaltry PAP enrollment for a flat $69.95 per month — so you never face a gap in Kovaltry hemophilia A therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Kovaltry enrollment — so you never face a gap in your hemophilia A treatment.
Pharmacy Price Comparison
- Without assistance, Kovaltry costs tens of thousands per month. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Hemlibra (non-factor alt) | ~$40,000/mo | Alt SC prophylaxis |
| Specialty pharmacy | ~$15,000/mo | Save substantially |
| Hemophilia Treatment Center | ~$13,000/mo | Save substantially |
| Hospital pharmacy | ~$20,000/mo | Save substantially |
| 340B-eligible institution | ~$12,000/mo | Save substantially |
| Ext half-life FVIII (alt) | ~$20,000/mo | Extended half-life alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Kovaltry — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Kovaltry Prescription Program?
The Kovaltry Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Hemophilia care is best at Hemophilia Treatment Centers with multidisciplinary teams. Standard-half-life factor VIII remains a cornerstone for many patients.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Kovaltry assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Kovaltry is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Kovaltry:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $12,000–$20,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Kovaltry assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Kovaltry Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Kovaltry:
Kovaltry is a standard-half-life full-length recombinant factor VIII produced without human or animal plasma-derived additives. It treats hemophilia A bleeding episodes and provides routine prophylaxis to prevent bleeding.
How It Works:
Hemophilia A is a congenital deficiency of coagulation factor VIII — X-linked recessive inheritance, mostly affecting males. Severe hemophilia (<1% FVIII) causes spontaneous bleeding into joints, muscles, and other tissues. Untreated bleeding leads to joint damage (hemophilic arthropathy) and disability. Prophylactic factor VIII replacement prevents joint damage. Recombinant factor VIII replaces the missing coagulation factor. Full-length recombinant factor VIII (Kovaltry) uses the complete factor VIII protein produced in mammalian cell culture without human or animal plasma-derived additives — reducing infectious risk historically associated with plasma-derived products. Standard half-life ~10–12 hours requires prophylaxis 2–3 times weekly.
Form and Use:
Kovaltry IV infusion. Individualized dosing based on weight, factor VIII pharmacokinetics, bleeding pattern, and prophylaxis regimen. Given at home or a hemophilia treatment center. Individualized prophylaxis regimen through a Hemophilia Treatment Center.
Generic Availability:
No generic Kovaltry. Extensive hemophilia A therapies: standard-half-life factor VIII (Advate, Recombinate, Kogenate FS, Xyntha, Novoeight — all recombinant); extended-half-life factor VIII (Adynovate, Eloctate, Nuwiq, Afstyla, Esperoct, Jivi, Altuviiio — Altuviiio has the longest half-life). Non-factor therapies (Hemlibra — emicizumab bispecific antibody, weekly-to-monthly SC dosing revolutionized prophylaxis). Gene therapy (Roctavian — one-time IV gene therapy for severe hemophilia A adults, 2022). Bypassing agents for inhibitors (Novoseven, Feiba). Comprehensive Hemophilia Treatment Centers coordinate multidisciplinary care. National Hemophilia Foundation and Hemophilia Federation of America.
Warnings:
Development of inhibitors (neutralizing antibodies against factor VIII — screen periodically), hypersensitivity reactions (including anaphylaxis), embryo-fetal considerations. Other: infusion reactions, headache, injection site reactions. Hemophilia Treatment Center care is essential for inhibitor monitoring, individualized prophylaxis, and bleeding episode management.
FAQ (Frequently Asked Questions)
How much does Kovaltry cost without insurance?
$12,000–$20,000+ per month depending on weight and dosing frequency. Hemophilia care is among the most expensive in medicine — Patient Assistance Programs are essential.
How is Kovaltry different from other factor VIII products?
Standard-half-life full-length recombinant factor VIII produced without human or animal plasma-derived additives. Other standard-half-life options include Advate, Recombinate, Kogenate FS, Xyntha, Novoeight. Extended-half-life products (Adynovate, Eloctate, Altuviiio) offer less frequent dosing but higher cost. Choice by prescriber, patient factors, and insurance.
How does Kovaltry compare to Hemlibra?
Different classes. Kovaltry is factor VIII replacement (IV). Hemlibra (emicizumab) is a bispecific antibody that mimics factor VIII function — SC dosing weekly to monthly. Hemlibra revolutionized hemophilia A prophylaxis. It is not for treatment of active bleeding (factor VIII replacement or bypassing agents are still needed for breakthrough bleeds). Both are appropriate choices depending on individual factors.
Should I consider extended half-life factor VIII?
Extended half-life factor VIII products (Adynovate, Eloctate, Altuviiio) enable less frequent prophylaxis dosing — a convenience advantage but higher cost. Discuss with a Hemophilia Treatment Center; pharmacokinetic studies help individualize the regimen.
What are Kovaltry side effects?
Generally well-tolerated. Risk of factor VIII inhibitors (neutralizing antibodies — screen periodically), hypersensitivity reactions, infusion reactions, headache, injection site reactions. Long-term surveillance for inhibitor development is critical.
Take Control of Your Medication Costs
Hemophilia A treatment is among the most expensive in medicine — accessible therapy is critical. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.